StemCell Therapy

Lip Augmentation Using Fat Stem Cells

By: Regenix Clinics

Read more:
Lip Augmentation Using Fat Stem Cells - Video

MIAMI (PRWEB) October 22, 2014

More than 900 physicians researchers and regenerative medicine experts from around the world attended the First International Symposium on Stem Cells and Regenerative Medicine, held in Buenos Aires, Argentina Oct. 2-4, 2014.

The event, hosted by Global Stem Cells Group in partnership with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, offered an opportunity for many of the worlds most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.

An interdisciplinary team of leading international stem cell experts provided a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who served as featured speakers at the event included:

Lord David Harrell, PhD., a scientific leader recognized nationally, internationally recognized expert in neuroscience and regenerative medicine and a member of the Global Stem Cells Group Advisory Board spoke on spoke on the cellular composition of bone marrow with a focus on stem and progenitor cell activities of bone marrow stem and progenitor cells.

Joseph Purita, M.D., Director of The Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, member of the Global Stem Cells Group Advisory Board and a pioneer in the use of stem cells and platelet rich plasma for a variety of orthopedic conditions, spoke about the use of PRP and stem cell injections for treatment of musculoskeletal conditions. He detailed cutting-edge treatments he now offers to his clinic patients, including extensive use of platelet-rich plasma in conjunction with bone marrow stem cells (BMAC), adipose stem cells (SVF) and fat grafts.

Vasilis Paspaliaris, M.D., CEO of Adistem, Ltd., a member of the Global Stem Cells Group Advisory Board and a thought-leading and highly experienced clinical pharmacologist and medical scientist discussed the proven differences in efficacy between the mesenchyme stem cells (MSCs) of a young donor and those of an aging donor, primarily due to the younger donor cells ability to secrete more trophic factors.

According to Benito Novas, Global Stem Cells Group CEO, the world-class event was well received at a time when the field of regenerative medicine is on the verge of changing medical science forever.

We wanted the symposium to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing, Novas says. We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physicians office and I believe we achieved our goals with this symposium.

Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices.

Link:
More than 900 Physicians Converge on Buenos Aires for ...

MIAMI (PRWEB) October 22, 2014

More than 900 physicians researchers and regenerative medicine experts from around the world attended the First International Symposium on Stem Cells and Regenerative Medicine, held in Buenos Aires, Argentina Oct. 2-4, 2014.

The event, hosted by Global Stem Cells Group in partnership with Julio Ferreira, M.D., President of the South American Academy Cosmetic Surgery, offered an opportunity for many of the worlds most respected authorities on stem cell and regenerative medicine to showcase advancements in research and therapies on a global level.

An interdisciplinary team of leading international stem cell experts provided a full day of high-level scientific lectures geared to medical professionals. Pioneers and luminaries in stem cell medicine who served as featured speakers at the event included:

Lord David Harrell, PhD., a scientific leader recognized nationally, internationally recognized expert in neuroscience and regenerative medicine and a member of the Global Stem Cells Group Advisory Board spoke on spoke on the cellular composition of bone marrow with a focus on stem and progenitor cell activities of bone marrow stem and progenitor cells.

Joseph Purita, M.D., Director of The Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, member of the Global Stem Cells Group Advisory Board and a pioneer in the use of stem cells and platelet rich plasma for a variety of orthopedic conditions, spoke about the use of PRP and stem cell injections for treatment of musculoskeletal conditions. He detailed cutting-edge treatments he now offers to his clinic patients, including extensive use of platelet-rich plasma in conjunction with bone marrow stem cells (BMAC), adipose stem cells (SVF) and fat grafts.

Vasilis Paspaliaris, M.D., CEO of Adistem, Ltd., a member of the Global Stem Cells Group Advisory Board and a thought-leading and highly experienced clinical pharmacologist and medical scientist discussed the proven differences in efficacy between the mesenchyme stem cells (MSCs) of a young donor and those of an aging donor, primarily due to the younger donor cells ability to secrete more trophic factors.

According to Benito Novas, Global Stem Cells Group CEO, the world-class event was well received at a time when the field of regenerative medicine is on the verge of changing medical science forever.

We wanted the symposium to help clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing, Novas says. We set out to establish a dialogue between researchers and practitioners in order to help move stem cell therapies from the lab to the physicians office and I believe we achieved our goals with this symposium.

Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices.

Read more:
More than 900 Physicians Converge on Buenos Aires for Global Stem Cells Groups First International Symposium on Stem ...

PUBLIC RELEASE DATE:

22-Oct-2014

Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf

NEW YORK, NY (October 22, 2014) The New York Stem Cell Foundation (NYSCF) Research Institute, through the launch of its repository in 2015, will provide for the first time the largest-ever number of stem cell lines available to the scientific research community. Initially, over 600 induced pluripotent stem (iPS) cell lines and 1,000 cultured fibroblasts from over 1,000 unique human subjects will be made available, with an increasing number available in the first year. To collect these samples, NYSCF set up a rigorous human subjects system that protects patients and allows for the safe and anonymous collection of samples from people interested in participating in research.

A pilot of over 200 of NYSCF's iPS cell lines is already searchable on an online database. The pilot includes panels of iPS cell lines generated from donors affected by specific diseases such as type 1 diabetes, Parkinson's disease, and multiple sclerosis, as well as a diversity panel of presumed healthy donors from a wide range of genetic backgrounds representing the United States Census. These panels, curated to provide ideal initial cohorts for studying each area, include subjects ranging in age of disease onset, and are gender matched. Other panels that will be available in 2015 include Alzheimer's disease, schizophrenia, Juvenile Batten disease, and Charcot-Marie-Tooth disease.

"NYSCF's mission is to develop new treatments for patients. Building the necessary infrastructure and making resources available to scientists around the world to further everyone's research are critical steps in accomplishing this goal," said Susan L. Solomon, CEO of The New York Stem Cell Foundation.

NYSCF has developed the technology needed to create a large collection of stem cell lines representing the world's population. This platform, known as the NYSCF Global Stem Cell ArrayTM, is an automated robotic system for stem cell production and is capable of generating 200 iPS cell lines a month from patients with various diseases and conditions and from all genetic backgrounds. The NYSCF Global Stem Cell ArrayTM is also used for stem cell differentiation and drug screening.

Currently available in the online database that was developed in collaboration with eagle-i Network, of the Harvard Catalyst, is a pilot set of approximately 200 iPS cell lines and related information about the patients. This open source, open access resource discovery platform makes the cell lines and related information available to the public on a user-friendly, web-based, searchable system. This is one example of NYSCF's efforts to reduce duplicative research and enable even broader collaborative research efforts via data sharing and analysis. NYSCF continues to play a key role in connecting the dots between patients, scientists, funders, and outside researchers that all need access to biological samples.

"The NYSCF repository will be a critical complement to other existing efforts which are limited in their ability to distribute on a global scale. I believe that this NYSCF effort wholly supported by philanthropy will help accelerate the use of iPS cell based technology," said Dr. Mahendra Rao, NYSCF Vice President of Regenerative Medicine.

To develop these resources, NYSCF has partnered with over 50 disease foundations, academic institutions, pharmaceutical companies, and government entities, including the Parkinson's Progression Markers Initiative (PPMI), PersonalGenomes.org, the Beyond Batten Disease Foundation, among several others. NYSCF also participates in and drives a number of large-scale multi stakeholder initiatives including government and international efforts. One such example is the Cure Alzheimer's Fund Stem Cell Consortium, a group consisting of six institutions, including NYSCF, directly investigating, for the first time, brain cells in petri dishes from individual patients who have the common sporadic form of Alzheimer's disease.

Originally posted here:
The New York Stem Cell Foundation Research Institute announces largest-ever stem cell repository

Contact Information

Available for logged-in reporters only

Newswise Scientists have described a way to convert human skin cells directly into a specific type of brain cell affected by Huntingtons disease, an ultimately fatal neurodegenerative disorder. Unlike other techniques that turn one cell type into another, this new process does not pass through a stem cell phase, avoiding the production of multiple cell types, the studys authors report.

The researchers, at Washington University School of Medicine in St. Louis, demonstrated that these converted cells survived at least six months after injection into the brains of mice and behaved similarly to native cells in the brain.

Not only did these transplanted cells survive in the mouse brain, they showed functional properties similar to those of native cells, said senior author Andrew S. Yoo, PhD, assistant professor of developmental biology. These cells are known to extend projections into certain brain regions. And we found the human transplanted cells also connected to these distant targets in the mouse brain. Thats a landmark point about this paper.

The work appears Oct. 22 in the journal Neuron.

The investigators produced a specific type of brain cell called medium spiny neurons, which are important for controlling movement. They are the primary cells affected in Huntingtons disease, an inherited genetic disorder that causes involuntary muscle movements and cognitive decline usually beginning in middle-adulthood. Patients with the condition live about 20 years following the onset of symptoms, which steadily worsen over time.

The research involved adult human skin cells, rather than more commonly studied mouse cells or even human cells at an earlier stage of development. In regard to potential future therapies, the ability to convert adult human cells presents the possibility of using a patients own skin cells, which are easily accessible and wont be rejected by the immune system.

To reprogram these cells, Yoo and his colleagues put the skin cells in an environment that closely mimics the environment of brain cells. They knew from past work that exposure to two small molecules of RNA, a close chemical cousin of DNA, could turn skin cells into a mix of different types of neurons.

In a skin cell, the DNA instructions for how to be a brain cell, or any other type of cell, is neatly packed away, unused. In past research published in Nature, Yoo and his colleagues showed that exposure to two microRNAs called miR-9 and miR-124 altered the machinery that governs packaging of DNA. Though the investigators still are unraveling the details of this complex process, these microRNAs appear to be opening up the tightly packaged sections of DNA important for brain cells, allowing expression of genes governing development and function of neurons.

See the article here:
Human Skin Cells Reprogrammed Directly Into Brain Cells

Bone Marrow-Derived Stem Cell Prolotherapy
Stem Cell Prolotherapy is a procedure in which adult mesenchymal stem cells are transplanted directly into the damaged tissue or injury and promotes healing. Stem cells are the repairmen...

By: Kab S. Hong M.D.

See the original post here:
Bone Marrow-Derived Stem Cell Prolotherapy - Video

Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts?
http://www.burbankdentalimplants.com/blog/ In this video, I described what is PRP and PRF and how to concentrate growth factors, stem cells and molecular enhancers made from your own blood...

By: Ramsey Amin

Read this article:
Do I Need PRP/PRF/PDGF/BMP For Dental Implants and Bone grafts? - Video

Stem Cells, Regenerative Medicine and Policy Impediments to the New Future
Oct. 21, 2014 Baker Institute nonresident scholar Deepak Srivastava explores the current and future potential of stem cells and regenerative medicine.

By: BakerInstitute

See original here:
Stem Cells, Regenerative Medicine and Policy Impediments to the New Future - Video

PUBLIC RELEASE DATE:

20-Oct-2014

Contact: David McKeon 212-365-7440 New York Stem Cell Foundation @nyscf

Leaders in translational stem cell research from around the world will present the latest advances in stem cell science that are leading to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Ninth Annual Translational Stem Cell Research Conference.

The opening day of the conference includes a panel discussion on large scale, big data stem cell and genetic initiatives moderated by Susan L. Solomon, JD, CEO and Co-founder of The New York Stem Cell Foundation (NYSCF), with panelists George Church, PhD, Harvard Medical School; John Greally, PhD, Albert Einstein College of Medicine; Scott Noggle, PhD, The NYSCF Research Institute; and Eric Schadt, PhD, the Icahn School of Medicine at Mount Sinai.

Later that day, a discussion on neurodegeneration includes Kevin Eggan, PhD, Harvard University and the NYSCF Research Institute, who will discuss his research identifying an existing drug candidate that may be of use treating ALS and is entering clinical trials in the coming year. The following session on cell reprogramming and cancer includes Michael Milone, MD, PhD, University of Pennsylvania, who will discuss recent research results from his lab and his colleagues including the results of a clinical trial for leukemia featured in The New York Times last week. The first day closes with a conversation on personalized medicine featuring Dieter Egli, PhD, NYSCF Robertson Investigator at the NYSCF Research Institute and Columbia University; Rudolf Jaenisch, MD, The Whitehead Institute; and Sir Ian Wilmut, FRS, FRSE, University of Edinburgh.

On October 23, the day will begin with remarks by Kenneth Adams and Kyle Kimball, President of the Empire State Development Corporation and President of the New York City Economic Development Corporation, respectively. The session on translating innovation from the laboratory to the clinic features Stephen Chang, PhD, of the NYSCF Research Institute and Richard Pearse, PhD, of the Harvard Catalyst and eagle-i Network who will discuss their collaboration on the first publicly available induced pluripotent stem cell database. The day will close with a presentation on induced neuronal cells and cell transdifferentiation from the 2014 NYSCF Robertson Stem Cell Prize recipient, Marius Wernig, MD, PhD, of Stanford University School of Medicine.

Sir Ian Wilmut will give the keynote address on October 22nd and Dr. Rudolf Jaenisch will give the keynote address on the last day of the conference.

The full conference agenda can be found at http://www.nyscf.org/conference

###

See the original post:
Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference

La Jolla, CA (PRWEB) October 21, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study in partnership with Stem Cell Research Centre for Osteoarthritis. StemGenex and Stem Cell Research Centre (SCRC) believe that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

There are currently 21 million people in the U.S. alone, who suffer from Osteoarthritis. The most common symptoms are joint pain and stiffness which most commonly affect the neck, lower back, knees, shoulders and hips. These symptoms gradually worsen over time ultimately leading to the need for a total joint replacement procedure. StemGenex believe their new clinical study may provide patients improved mobility, significantly reduced pain and ultimately a better quality of life without needing joint replacement surgery.

This clinical study makes stem cell therapy for osteoarthritis accessible to the millions of individuals currently struggling with this painful disease. The protocol used in these stem cell treatments is unique to StemGenex and SCRC, having the possibility of being more effective than other stem cell treatments currently available. These treatments will utilize a multiple administration method which also includes injections precisely targeting the joint space. StemGenex believes these treatments may be able to keep patients from needing joint replacement surgery in the future, due to regeneration of cartilage in the joint.

This clinical study will be conducted under the leadership of the principal investigator,Dr. Jeremiah McDole, Ph.D. Dr. McDole states, We are excited to begin enrolling for this new study. We have high expectations for what we will learn and what advancements can ultimately be implemented. Of course, our focus is always set toward the near future and what can be done to help improve the lives of those individuals with Osteoarthritis.

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval of Stem Cell Research Centre (SCRC). There are many patients who are exploring stem cell therapy for osteoarthritis and it is important they have access to top-tier stem cell therapy. By providing patients access to stem cell studies registered through The National Institutes of Health, patients now have the ability to choose treatment that focuses on both safety and efficacy.

Rita Alexander, founder and president of StemGenex stated With so many people suffering from Osteoarthritis its absolutely wonderful to provide a treatment that has not only shown efficacy but also to be minimally invasive. Over the last several years we have observed significant improvement in the symptoms of Osteoarthritis patients through stem cell treatment. Through these registered clinical studies, we will now be able to publish our findings over the next few years.

This clinical study follows on the heels of StemGenex latest clinical studies for both Parkinsons disease and Multiple Sclerosis. Stem cell treatment studies are currently being offered by StemGenex partnering with Stem Cell Research Centre (SCRC) to patients diagnosed with Osteoarthritis as well as degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative conditions including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com

More here:
StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce
Do It Yourself - Stem Cell Hair Therapy : http://placesiana.com/stem-cell-hair-loss-therapy Imagine becoming a healthier, much younger, better looking you? Infused with a potent growth factor...

By: Sam Jeunesse

Read more from the original source:
Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce - Video

Aarkstore -Stem Cell Research in Cardiology
This market insight report on Stem Cell Research in Cardiology emphasizes on the market for stem cells in Cardiology. The study is segmented by Source (Allogenic and Autogenic) and by Type...

By: sangam Jain

See original here:
Aarkstore -Stem Cell Research in Cardiology - Video

The Stem Cell #39;s Journey
DescriptionStem cells have the ability to transform into many different cell types, but Stemmy the stem cell possesses a unique gift: he can transform cells around him into duplicates of himself....

By: Jeff Alu

More here:
The Stem Cell's Journey - Video

Understanding Niche Cells | Science: Out of the Box
Johns Hopkins cell biologist Erika Matunis explains how understanding the cells that take care of stem cells may shed light on cancer. To see more Science: Out of the Box videos, visit http://www...

By: Johns Hopkins Medicine

See original here:
Understanding Niche Cells | Science: Out of the Box - Video

TWIS Minion / Science Island Hangout October 16, 2014
Amy Lynn Thompson, Ed Dyer, AJ Smith and Dale Liebrecht talking about Mars missions, the Milky Way being a bully, Black Holes, the mighty stem cells healing hearts and eyes and more. Show...

By: Edward Dyer

Read the original here:
TWIS Minion / Science Island Hangout October 16, 2014 - Video

Dr Nathan Newman explains Stem Cells
Dr. Nathan Newman explains how adult stem cells are revolutionizing medicine and how they #39;re already being used in treatment of cosmetic and reconstructive to rejuvenate damaged tissues and...

By: Yingyao

Read more from the original source:
Dr Nathan Newman explains Stem Cells - Video

Can Stem Cell Injections Cure Blindness?
Stem cells may be able to cure blindness through injecting them into the eyes of people who are blind. The procedure worked over a three year period in restoring the vision of eighteen patients...

By: TheLipTV

See the original post:
Can Stem Cell Injections Cure Blindness? - Video

FranchiseStemcell Fat Stem Cell Therapy Anti Aging
Fat Stem Cell Therapy Anti Aging .

By: Franchise StemCell

Follow this link:
FranchiseStemcell Fat Stem Cell Therapy Anti Aging - Video

MEDS-380
Stem cells have captured the imaginations of scientists, physicians, and the general public for their ability to revolutionize not only how we treat diseases but the foundations of life itself....

By: Erin Yamauchi

Originally posted here:
MEDS-380 - Video

Dr Charles Krome Stem Cell Therapy
This video is about Dr Charles Krome Stem Cell Therapy.

By: John lore

Here is the original post:
Dr Charles Krome Stem Cell Therapy - Video